Go to content

Publications

428 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Organisation chart 2023

    Organisation chart 2023

    Publication | 21-09-2023

  2. GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

    The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

    Report | 11-07-2023

  3. GVS advice avacopan (Tavneos®) for the treatment of certain patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

    The National Health Care Institute has assessed whether avacopan (Tavneos®) can be included in the Medicine Reimbursement System ...

    Report | 15-06-2023

  4. GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults

    The National Health Care Institute has assessed whether the hepatitis B vaccine PreHevbri® can be included in the Medicine ...

    Report | 02-06-2023

  5. GVS advice lasmiditan (Rayvow®) for the treatment of migraine

    The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System ...

    Report | 23-05-2023

  6. Advice on the clustering of combination products and ghost clusters in GVS (part 4)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  7. Advice on the clustering of combination products and ghost clusters in GVS (part 3)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  8. GVS advice dapagliflozin (Forxiga®) extension of List 2 conditions

    The National Health Care Institute has assessed whether the reimbursement conditions for dapagliflozin (Forxiga®) can be ...

    Report | 23-05-2023

  9. Advice on the clustering of combination products and ghost clusters in GVS (part 2)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  10. Package advice lenvatinib (Kisplix®) in combination with pembrolizumab for the treatment of renal cell carcinoma

    The National Health Care Institute has assessed whether the medicinal product lenvatinib (Kisplix®) in combination with ...

    Report | 15-05-2023

Go to